Unicycive Therapeutics Announces Resubmission of New Drug Application (NDA) for Oxylanthanum Carbonate (OLC)
MWN-AI** Summary
Unicycive Therapeutics, Inc. (Nasdaq: UNCY) has announced the resubmission of its New Drug Application (NDA) for oxylanthanum carbonate (OLC) to the U.S. Food and Drug Administration (FDA). OLC is an investigational oral phosphate binder designed to treat hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis. The resubmission follows significant compliance progress made by the company's manufacturing vendor, which was previously cited for deficiencies by the FDA.
CEO Dr. Shalabh Gupta expressed confidence in the company's position to further the regulatory approval process due to a cash runway extending into 2027. Unicycive held a Type A meeting with the FDA in September 2025, where feedback was provided on addressing the deficiencies noted in the FDA's Complete Response Letter (CRL) issued in June 2025. The FDA identified no additional issues following the responses to the earlier cited deficiencies. Furthermore, during a subsequent inspection by European Union authorities, no deficiencies were found at the original manufacturing site.
OLC utilizes proprietary nanoparticle technology offering high phosphate binding potency, potentially minimizing the pill burden for patients compared to existing treatment options. The NDA submission incorporates data from three clinical studies and is backed by a strong patent portfolio that extends exclusivity until 2031, with possibilities for extension until 2035.
Uncontrolled hyperphosphatemia poses serious risks for CKD patients, making effective treatment essential. Unicycive's pursuit of OLC aims to address this critical health issue affecting a significant patient population reliant on dialysis for kidney function support. The company's other investigational treatment, UNI-494, targets acute kidney injury and has received orphan drug designation for its potential in kidney transplant patients.
MWN-AI** Analysis
Unicycive Therapeutics’ recent announcement regarding the resubmission of its New Drug Application (NDA) for oxylanthanum carbonate (OLC) offers intriguing investment prospects but also necessitates careful consideration of associated risks. As a clinical-stage biotechnology firm focused on kidney disease treatments, Unicycive's progress in obtaining FDA approval for OLC—a novel oral phosphate binder—could position it favorably in a market with substantial unmet needs.
OLC targets hyperphosphatemia, a common condition in patients with chronic kidney disease (CKD) undergoing dialysis. The favorable response from the FDA regarding manufacturing compliance hints at a path toward potential approval. The efficacy of OLC in simplifying treatment regimens through reduced pill burden could lead to enhanced patient adherence compared to existing therapies, making it attractive in an increasingly competitive pharmaceutical landscape.
However, investors should heed the historical context: Unicycive previously faced setbacks, receiving a Complete Response Letter (CRL) in June 2025. Despite encouraging recent inspections and progress, the market trend indicates that investors often react cautiously to biotech stocks until clear regulatory approvals are in place. The company’s cash runway extending into 2027 reduces immediate liquidity concerns, yet the dependency on FDA approval introduces volatility.
With the Prescription Drug User Fee Act (PDUFA) guidelines indicating a timeline for potential FDA feedback, including a 30-day review acknowledgment from the NDA submission, investors should monitor this critical juncture closely. A favorable decision could trigger significant stock appreciation, while further delays may lead to increased skepticism and downward pressure.
In conclusion, while Unicycive presents an intriguing high-risk, high-reward scenario, investors are advised to balance potential gains against the uncertainties inherent in the biotech sector and remain vigilant regarding forthcoming regulatory reviews.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LOS ALTOS, Calif., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that it has resubmitted its 505(b)(2) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for oxylanthanum carbonate (OLC), the Company’s investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis.
“Our original third-party manufacturing vendor has made significant progress toward regaining FDA compliance, allowing us to resubmit the OLC NDA as planned,” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. “With a cash runway into 2027, we are well-positioned to complete the regulatory approval process for OLC so we can prepare to bring this important treatment option to dialysis patients with hyperphosphatemia as soon as possible.”
The NDA for OLC was resubmitted based on continued progress by the original third-party manufacturing vendor in resolving FDA-cited deficiencies and demonstrating inspection readiness. Unicycive previously discussed these milestones during a Type A meeting with the FDA in September 2025, which was held to obtain feedback and alignment on resolving the single deficiency identified in the Company’s Complete Response Letter (CRL) related to the compliance status of the vendor. No additional issues were raised by the FDA. Following receipt of the CRL in June 2025, European Union regulatory authorities inspected the original third-party manufacturing vendor and identified no deficiencies.
The Prescription Drug User Fee Act target guidelines for NDA resubmissions include acknowledgment of acceptance for review within 30 days of submission, and completion of submission review within 6 months.
About Oxylanthanum Carbonate (OLC)
OLC is an investigational oral phosphate binder that leverages proprietary nanoparticle technology to deliver high phosphate binding potency, reducing the number and size of pills that patients must take to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. Its potential best-in-class profile may have meaningful patient adherence benefits over currently available treatment options as it requires a lower pill burden.
Unicycive is seeking FDA approval of OLC via the 505(b)(2) regulatory pathway. The NDA submission package is based on data from three clinical studies (a Phase 1 study in healthy volunteers, a bioequivalence study in healthy volunteers, and a tolerability study of OLC in CKD patients on dialysis), multiple preclinical studies, and the chemistry, manufacturing and controls (CMC) data. OLC is protected by a strong global patent portfolio including issued patents on composition of matter with exclusivity until 2031, and with the potential for patent term extension until 2035.
About Hyperphosphatemia
Hyperphosphatemia is a serious medical condition that occurs in nearly all patients with End Stage Renal Disease (ESRD). Annually there are over 450,000 individuals in the U.S. that require medication to control their phosphate levels.1 Uncontrolled hyperphosphatemia is strongly associated with increased death and hospitalization for CKD patients on dialysis. Treatment of hyperphosphatemia is aimed at lowering serum phosphate levels via two means: (1) restricting dietary phosphorus intake; and (2) using, on a daily basis, and with each meal, oral phosphate binding drugs that facilitate fecal elimination of dietary phosphate rather than its absorption from the gastrointestinal tract into the bloodstream.
1Flythe JE. Dialysis-Past, Present, and Future: A Kidney360 Perspectives Series. Kidney360. 2023 May 1;4(5):567-568. doi: 10.34067/KID.0000000000000145.
About Unicycive Therapeutics
Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information about Unicycive, visit Unicycive.com and follow us on LinkedIn and X.
Forward-looking statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Unicycive's expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, which could seriously harm our financial condition and increase our costs and expenses; our need to raise substantial additional capital in the future to fund our continuing operations and the development and commercialization of our current product candidates and future product candidates; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; risks related to delays in obtaining or failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; and our failure, or the failure of our third-party manufacturers, or their subcontractors, to comply with cGMPs or other applicable regulations, which could result in sanctions being imposed on us or the manufacturers, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates, operating restrictions and criminal prosecutions, any of which could adversely affect supplies of our product candidates and harm our business and results of operations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kevin Gardner
LifeSci Advisors
kgardner@lifesciadvisors.com
Media Contact:
Layne Litsinger
Real Chemistry
llitsinger@realchemistry.com
SOURCE: Unicycive Therapeutics, Inc.
FAQ**
What are the key milestones for Unicycive Therapeutics Inc. UNCY in the regulatory approval process for oxylanthanum carbonate (OLC) and how do they plan to address potential delays or challenges?
How does Unicycive Therapeutics Inc. UNCY's oxylanthanum carbonate (OLC) compare in efficacy and patient adherence to existing treatments for hyperphosphatemia in chronic kidney disease?
What is the strategic plan for Unicycive Therapeutics Inc. UNCY to secure additional funding or partnerships to support the ongoing development of OLC and its second investigational treatment, UNI-494?
How do potential changes in FDA regulations or competitive market dynamics affect Unicycive Therapeutics Inc. UNCY's position and strategy within the kidney disease treatment landscape?
**MWN-AI FAQ is based on asking OpenAI questions about Unicycive Therapeutics Inc. (NASDAQ: UNCY).
NASDAQ: UNCY
UNCY Trading
-3.12% G/L:
$6.52 Last:
492,517 Volume:
$6.72 Open:
